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Abstract
Children with cancer are only eligible for phase I clinical trials (P1Ts) when no known curative 
therapy remains. However, the primary aims of P1Ts are not focused on directly benefiting 
participants. This raises ethical concerns that can be best evaluated by exploring the experiences of 
participants. An empirical phenomenology study, using an adapted Colaizzi method, was 
conducted of 11 parents’ lived experiences of their child’s participation in a pediatric oncology 
P1T.
Study findings were that parents’ experiences reflected what it meant to have a child fighting to 
survive high-risk cancer. Although elements specific to P1T participation were identified, more 
pervasive was parents’ sense of running out of time to find an effective treatment and needing to 
use time they had with their child well. Even though some problems were identified, overall 
parents did not regret their child’s P1T participation and would recommend P1Ts to other parents 
of children with cancer.
Introduction
Cancer persists as the second most common cause of death (after accidents) for children 
aged 1 to 14 years, and the incidence of cancer in children and adolescents is continuing to 
increase (Siegel, Miller, & Jemal, 2016; Ward, Desantis, Robbins, Kohler, & Jemal, 2014). 
However, survival rates for childhood cancers are improving; between 1975 and 2011 
overall five-year survival rates for childhood cancer improved by over 43% (to 83%) (Siegel 
et al., 2016; Ward et al., 2014). These improvements in childhood cancer outcomes are 
attributed to better therapies and high levels of participation in clinical trials (Hudson, 
Meyer, & Pui, 2015; Weber et al., 2014).
Phase I clinical trials (P1Ts) are the critical first stage of clinical trials, and determine the 
recommend dosage and test the safety of new therapies (Craft et al., 2009; Kim et al., 2008; 
Lee, Skolnik, & Adamson, 2005; Weber et al., 2014). In pediatrics, P1Ts involve testing an 
investigational therapy (either as a single agent or a novel combination of agents) not 
approved for use in children. Enrollment in P1Ts is typically limited to cohorts of three to 
six children at a time. To minimize the risk of untoward adverse events, the dose of the 
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investigational therapy administered is incrementally increased in consecutive cohorts based 
on how the therapy is tolerated, until a maximum tolerated or recommended dose is 
established. Additional monitoring and research-only procedures are required of P1T 
participants, to ensure their safety and to understand the pharmacology of the therapy in 
children. Despite the challenges involved, P1Ts are necessary for developing new therapies 
that will improve outcomes for children with cancer.
The Declaration of Helsinki requires that “while the primary purpose of medical research is 
to generate new knowledge, this goal can never take precedence over the rights and interests 
of individual research subjects” (World Medical Association, 2013). The ethical challenge 
inherent in pediatric oncology P1Ts is that the primary aims of these trials are focused on 
developing new therapies and are not intended to provide direct benefit to participants. Due 
to the investigational nature of the new therapies being tested, children are only eligible to 
participate in P1Ts when their cancer is considered incurable (Bautista et al., 2015; Crites & 
Kodish, 2013; Deatrick, Angst, & Moore, 2002). The median life expectancy of children 
with relapsed cancer enrolled in a P1T is less than seven months (Bautista et al., 2015; Kim 
et al., 2008; Morgenstern et al., 2014). Despite this, clinicians and parents pursue P1Ts for 
children with cancer based on hope that the investigational therapy being tested will improve 
the child’s disease prognosis (Barrera, D'Agostino, Gammon, Spencer, & Baruchel, 2005; 
Crites & Kodish, 2013; Deatrick et al., 2002; Oppenheim, Geoerger, & Hartmann, 2005; 
Weber et al., 2014).
To address the ethical challenges of pediatric oncology P1Ts, it is important to understand 
the experiences of participants in these trials. Experiences with P1Ts may vary widely given 
the toxicities of the P1T therapy, distance travelled to the P1T center, previous relationship 
with the P1T medical team, response of the child’s cancer to the P1T therapy, and previous 
clinical trial experiences. Although there are numerous studies on the P1T consenting 
process (Barrera et al., 2005; Cousino et al., 2012; Deatrick et al., 2002; Hinds et al., 2005; 
Hinds et al., 1997; Hinds et al., 2009; Levine et al., 2015; Marshall et al., 2012; Maurer et 
al., 2010; Miller et al., 2013; Oppenheim et al., 2005), no studies have been done with 
children with cancer or their parents on the experience of actually participating in a P1T.
The purpose of this study was to describe the meaning of the experience of P1T participation 
from the perspective of parents of children with cancer. A descriptive, cross-sectional, 
empirical phenomenological study was conducted using an adapted version of Colaizzi’s 
method, based on Husserl’s philosophy of phenomenology (Colaizzi, 1978; Haase, 1987). 
The goal of Colaizzi’s method of empirical phenomenology is to generate an exhaustive 
description of the phenomenon, and from the exhaustive description to describe the essential 
structure of the experience (Colaizzi, 1978). Identification of the essential structure is crucial 
to meaningfully understand the experience of a phenomenon, and how the experience of a 
phenomenon impacts behavior and perceptions (Colaizzi, 1978).
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Methods
Setting
Parent recruitment occurred at two time points. First, a pilot interview was conducted with 
one parent recruited by the first author, based on prior knowledge of the parent’s advocacy 
efforts. The main study then recruited participants from two pediatric academic medical 
centers in the Midwest United States that conduct pediatric oncology P1Ts. Parents were 
also recruited for the main study from national childhood cancer support and advocacy 
groups that were not affiliated with either medical center.
Sample
The purposive sample consisted of parents of children with cancer who participated in a 
P1T. Sample size in phenomenological studies is not determined in advance. Rather, 
sampling continues until data analysis yields thematic redundancy, and generally ranges 
between 3 and 15 participants (Creswell, 2013; Englander, 2012; Lincoln & Guba, 1985; 
Morse, 1995; Palys, 2008; Speziale, Streubert, & Carpenter, 2011; Starks & Trinidad, 2007). 
No effort was made to control for demographic variables or clinical history since empirical 
phenomenology is used to describe the commonalities of experiences, even within a diverse 
sample (Colaizzi, 1978). Efforts were made to ensure the sample included parents of 
children with cancer who had a diverse range of positive and negative outcomes following 
the P1T.
Parent was defined as anyone who served in the role of primary caregiver (e.g. biological 
parent, guardian, grandparent). To capture a complete picture of all parents’ experiences, up 
to two parents were interviewed for each eligible child. Parent inclusion criteria were: (1) 
age ≥ 18; (2) self-identification as primary caregiver of child; (3) fluency in English; and (4) 
having provided consent for child’s P1T participation. In addition, the parent’s child must 
have been: (1) enrolled in at least one pediatric oncology P1T in the United States; (2) aged 
< 18 during the P1T; and (3) removed from the P1T at least 60 days prior (to ensure that the 
off-study transition was fully experienced). Parents were ineligible if the child had died 
within the previous 60 days.
Recruitment
Institutional Research Board approval was obtained prior to screening or enrolling 
participants. Recruitment occurred between March and December 2016.
Parents were recruited at one medical center by the first author and at the second medical 
center by experienced pediatric oncology clinical research professionals. Parents were pre-
screened for eligibility by reviewing all participants enrolled in a P1T within the past four 
years. Potentially eligible participants were recruited using the method developed for 
research involving parents of deceased children (Hinds, Burghen, & Pritchard, 2007). 
Specifically, a recruitment-letter was sent from the phase I center with instructions for 
enrolling as well as opting out of further contact attempts. After a two-week waiting period, 
potential participants were contacted via telephone.
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Parents were also recruited from cancer support and advocacy groups by the first author. The 
first author contacted key leaders of the groups who, if they approved, released information 
about the study to members (i.e. recruitment materials including a link to a Facebook page). 
Potentially eligible parents then responded if interested in participating.
Parents who responded to a recruitment attempt completed the screening process and were 
given additional information about the study by the study team member who recruited them. 
After confirming participants’ interest and eligibility, a link was sent to an online Research 
Electronic Data Capture (REDCap™) survey via electronic mail that allowed participants to 
formally agree to participate and begin study procedures (Harris et al., 2009). If desired, 
participants could complete the agreement to participate and other REDCap™ surveys in 
writing.
Procedures
Parents who agreed to participate completed the demographic form and provided their 
interview availability through REDCap™. The interview date and time was agreed upon 
between the participant and the first author. The first author sent the interview question via 
email at least one day in advance of the interview (Hinds et al., 2007). Interviews were 
audio-recorded and done over the telephone by the first author at a time convenient to the 
parent. Seven to fourteen days after the interview, a follow-up call was made by another 
study team member to clarify any ambiguous details from the interview and to ensure no 
undue distress resulted from participation in this study. Lastly, the team member who 
recruited each participant manually extracted data from the child’s clinical trial record into 
the REDCap™ database. Completion of study-related procedures was monitored on a 
weekly basis by the first author and when needed follow-up reminder emails were sent to 
participants. Participants received a $50 gift card at the end of the study in recognition of 
their time and effort.
Demographic form—Participants electronically completed a demographic form via a 
REDCap™ survey. Questions included: child’s age at P1T enrollment, gender, race, 
ethnicity, type of cancer, education level, and school attendance at time of enrollment in the 
P1T; family configuration; household income; parent education level; living arrangements; 
distance to the P1T center; and details surrounding transitions on and off the P1T.
Phenomenological interview—The goal of empirical phenomenological interviews is to 
obtain clear, rich descriptions of participants’ experiences (Englander, 2012; Wimpenny & 
Gass, 2000). Of particular importance is ensuring that the participant describes their 
experiences without analysis or interpretation, using a small number of broad, open-ended 
questions (Colaizzi, 1978; Englander, 2012; Wimpenny & Gass, 2000). For this study, one 
broad data-generating question was asked:
I am interested in hearing what it was like when [child’s name] was enrolled in 
[that study/those studies]. I would like to hear as much about the experience as you 
can remember, including all the circumstances, perceptions, and conversations 
during [child’s name]’s time in the phase I [study/studies]. It is sometimes helpful 
to begin telling what it was like as a story, starting when you first learned about the 
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phase I [study/studies] through to the time [child’s name] was taken off the [study/
studies].
To ensure that the parent guided the discussion, there was no set agenda of topics to cover 
(Palys, 2008; Wimpenny & Gass, 2000). Probes such as: "Please tell me more about that" 
and "What did that mean to you?" were used to enhance depth of the discussion (Palys, 
2008; Wimpenny & Gass, 2000). After parents finished fully describing their experiences, if 
any of the following were not mentioned, the interviewer asked the parent for elaboration: 
learning about and enrolling their child on each P1T, receiving the first dose of each P1T 
therapy, and transitioning off each P1T. Lastly, the parent was asked if they had any advice 
for parents considering enrolling their child in a P1T, and if there were any other important 
events or people who impacted their P1T experience.
Clinical trial data extraction—After the phenomenological interview and follow-up call 
were completed, selected information was retrieved from the child’s clinical trial record and 
entered into the REDCap™ database by the team member who recruited each participant. 
This information included: type of trial, investigational therapy and its method of 
administration, concomitant medications, eating or drinking restrictions, required and 
optional observations included in the trial, toxicities and serious adverse events the child 
experienced, length of time on the trial, reason for removal from the trial, and results of 
disease evaluations.
Data Analysis
Interviews were audio-recorded and professionally transcribed by a contracted, Health 
Information Portability and Accountability Act (HIPAA)-approved provider Data were 
managed using NVivo™ software.
Steps of analysis, per the adapted Colaizzi method, included the following (Colaizzi, 1978; 
Haase, 1987). The first author began analysis by listening to the audio-recordings to: verify 
and correct any inaccuracies of the transcriptions, add comments to ensure the tone of the 
participant was captured (e.g. laughs, pauses, emphasis, sadness, etc.), and gain a sense of 
the experience as a whole. Steps two to four involved identification of substantive phrases, 
restatement of substantive phrases in general terms, and formulation of derived meanings 
(see Table 1 for examples). Step five involved development of themes and organization of 
themes into theme clusters and categories. Step six was to generate an exhaustive description 
of the experience. Step seven was to describe the essential structure of parents’ experiences 
of having a child participate in a P1T. Colaizzi’s method includes a final step of participant 
validation of research results which was not performed in this study (Colaizzi, 1978). 
Concerns existed surrounding participant validation because results of a phenomenological 
study cannot be appreciated without parents having a phenomenological attitude or a 
disciplinary perspective (Giorgi, 2006; Morse, Barrett, Mayan, Olson, & Spiers, 2008; 
Porter, 2007).
Data analysis occurred simultaneously with participant recruitment. Thematic redundancy 
was established when new themes no longer emerged from interview transcripts. The 
demographic form and clinical trial record were used to describe the sample, understand 
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details specific to the P1T in which the child was enrolled, inform parents’ descriptions of 
their experiences, and provide context for interpreting experiences.
Crucial elements of the empirical phenomenology method that were used included a 
phenomenological attitude adopted through bracketing and avoiding premature closure to 
the phenomenon, and imaginative variation to determine the essential structure of the 
phenomenon (Beck, Keddy, & Cohen, 1994; Colaizzi, 1978; Dowling, 2007; Gearing, 2004; 
Giorgi, 1997, 2006). Prior to beginning this study, the first author reflected in writing on 
personal and theoretical knowledge of the P1T experience. These reflections were used to 
recognize when the phenomenological attitude was compromised. In addition, a reflexive 
diary of decision-making, theme emergence, and personal responses was kept by the first 
author throughout interviewing and data analysis (Koch & Harrington, 1998; Kumar & 
Cavallaro, 2017). Lastly, the dissertation chair reviewed the first nine interview transcripts 
and weekly or bi-weekly assisted with data analysis to ensure that the phenomenological 
attitude was maintained, each step of the process was performed through discussion and 
consensus, and authors cared for themselves (Kumar & Cavallaro, 2017).
After data analysis was complete, two clinicians were contacted to enhance the clinical 
transferability of the findings (Guba, 1981; Lincoln & Guba, 1985). The first author sent the 
exhaustive description and essential structure to an experienced phase I physician and nurse 
who were asked to answer the following. (1) What ways do these findings ring true? (2) 
What ways do they not ring true? (3) How could these findings be useful in the design or 
conduct of pediatric oncology P1Ts? Primarily the clinicians’ feedback helped to frame 
aspects of the discussion section, although one idea in the exhaustive description was 
clarified through their feedback (i.e. the team parents “formed” was changed to the team 
parents “assembled”).
Findings
Description of Sample
The accrued sample consisted of 12 parents. Nine parents (75.0%) were recruited from 
pediatric medical centers, two parents (16.7%) from childhood cancer groups, and one 
parent (8.3%) who completed the pilot interview. The response rate at Medical Center 1 was 
35.3% (6 of 17 parents of children with cancer approached to participate enrolled in this 
study); the response rate at Medical Center 2 was 33.3% (3 of 9 approached). All eligible 
parents (100%, n=2) recruited through childhood cancer groups chose to enroll. Of the 
parents enrolled, one parent from Medical Center 1 completed the consent and demographic 
forms but did not follow through and complete the interview, resulting in an evaluable 
sample of 11 parents (91.7% retention rate). Mean interview length was 59.1 minutes 
(SD=15.1, range 29.9–85.3 minutes).
Parents were mostly female (81.8%, n=2 males) and white (100%) with non-Hispanic 
ethnicity (90.9%; one parent did not specify ethnicity). The mean age of the children with 
cancer was 11.2 years (SD=5.2, range 3–17 years) at enrollment to the first P1T. Only two 
parents enrolled were a couple; all other participants were parents of different children. Most 
of the children with cancer were deceased (60%, n=6), although two children were surviving 
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and still receiving treatment (20%) and two children were long-term survivors and off 
treatment (20%). The children participated in a total of 15 P1Ts, with a mean of 1.6 P1Ts 
per child (range 1 – 3; median 1). The number of grade 2 or greater toxicities that the 
children experienced during a P1T varied from 2 to 15 (median 7, mean 7.9, SD 4.7). The 
maximum toxicity grade experienced by the children during a P1T ranged from grade 2 to 
grade 5 (median grade 3). Although racial, ethnic, and social diversity was lacking in the 
sample, a strong diversity in P1T experiences was captured. P1T experiences included: being 
removed early in the first course of a P1T, participating in multiple P1Ts, dying 
unexpectedly during a P1T, achieving a full remission from P1T therapy, and actively 
participating / considering participating in another P1T. See Table 2 for further 
characteristics of the sample and their P1T experiences.
Theme Categories
Data analysis identified five main theme categories. Theme categories abstracted were: (1) 
Being the parent of a child with high-risk cancer; (2) Contending with high-risk cancer; (3) 
Perceptions of their child’s experiences; (4) The nature of P1T participation; and (5) 
Remembering and forgetting. As an exemplar, Table 3 provides a list of theme clusters and 
themes associated with the theme category ‘Being the parent of a child with high risk 
cancer’. In the text below, quotes from parents are linked to the original interview transcripts 
via a designation which reflects participant number followed by transcript line number.
Theme Category 1 - Being the parent of a child with high-risk cancer: “This is 
my child here”—The overall experience of being the parent of a child with high-risk 
cancer embodied the weight of being fully responsible for the child’s well-being and 
knowing that “it’s all on our shoulders”. This responsibility included the child’s inherent full 
reliance on the parent for all their needs. In addition, this responsibility necessitated that 
parents become an expert in their child’s cancer, find a way to help their child get better, 
protect their child from undue harm and distress, be vigilant, prioritize their child’s needs 
and desires over everything else, advocate for their child when needed, and encourage their 
child to keep trying. As one parent stated:
“I look at it kind of like … the movie … where he [the father] and his son are in the 
concentration camps and he's trying to shield his son from the horrors and trying to 
show him the beautiful aspects of life.”
This sense of total responsibility meant that parents felt like they knew their child and their 
child’s medical condition better than anyone, and they felt they did not have anyone to 
blame when treatments they agreed to did not work. “If something does happen, and 
knowing that you don't know, you just kind of got to accept it.”
Parents sought and primarily achieved alignment with their child regarding the treatment 
plan. They looked to the child for direction and strove for open parent / child 
communication, e.g. “That's the decision we have to let [her] make. If she wants to try 
another one [P1T], if she don't want to try another one, whatever it be.” Due to the parent’s 
underlying need for their child to agree and cooperate with the treatment plan, whenever 
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parent and child were misaligned, the parent sought ways to realign. “I didn’t want to be 
forceful …. I was just very hopeful that she would say, ‘yeah Mom, let’s do this’.”
Finally, being the parent of a child with high-risk cancer involved parental suffering. The 
emotional burdens parents faced resulted in intense angst – “that pit in my stomach” (see 
Table 3 for full list of emotional burdens). Underlying the burdens was the need to make 
good decisions on their child’s behalf and to ensure the time they had with their child was 
used well. “I just wish I'd had a little bit more power, a little bit more strength, a little bit 
more knowledge.”
Theme Category 2 - Contending with high-risk cancer: Fighting “this beast”—
Woven throughout parents’ P1T experiences was a pervasive struggle to contend with their 
child’s high-risk cancer. One parent described this as:
“You almost have a feeling of … hopelessness … you just kind of wonder from day 
to day, well is this the day that we're going to have something that is going to work? 
…even though you feel defeated, you still have that glimmer of hope that there's 
something that’s going to work. There's got to be something that's going to start 
shrinking it.”
The full continuum of the cancer journey, which extended from diagnosis to the child’s 
survival or death, was focused on overcoming the cancer, underscoring the importance of not 
wasting time with ineffective, intolerable, or unavailable treatments. Contending with the 
cancer was complicated by a perception of the child’s wellness that was separate from the 
child’s cancer status, and made it difficult to accept the cancer worsening. “[The doctor] 
said, ‘Um, the cancer is back.’ And I was like, ‘What?’ I mean she never, ever showed 
signs.”
The team parents assembled to help fight the child’s cancer consisted primarily of the 
medical team and close family members, although some parents fortified their team with 
support from other parents of children with similar cancer diagnoses. The processes involved 
with having a team to help in the struggle against the child’s cancer included aligning or 
connecting, becoming misaligned or disconnected, and managing misalignment or 
disconnectedness with team members. Parents who felt disconnected from medical team 
members were reluctant to share those concerns with the team. “It was kind of hard to bring 
up our anxieties... We were just prayerful that we were being pushed in this direction [to the 
P1T] for good reasons.”
Parents left no stone unturned in the search for treatments, but had specific requirements for 
acceptable treatment options based on anticipated impact on quality of life. Parents were 
aware that “you necessarily have to start looking at quality of life instead of quantity at some 
point.” Although parents clung to hope that the next treatment would help, they also felt 
challenged to begin thinking about stopping their search for treatment. Parents bore the 
burden of decision-making at potential stopping points as they had no choice but to make a 
choice. They conscientiously approached decision-making by “weighing everything out”, 
balancing potential risks and benefits with expected impact on quality of life. Parents were 
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generally able to be decisive in their decision-making, and not look back after decisions 
were made.
Being locked in this struggle against the child’s cancer necessitated finding ways to manage 
constant challenges and uncertainty day to day. “You're just on this moving treadmill and 
you're trying to keep up with the speed as it increases.” Parents managed by finding a new 
norm for their child and family, i.e. by getting “to where we could all breathe”. This resulted 
in a redefinition of what was considered truly difficult or problematic.
Parents transcended the day to day challenges and uncertainty of their child’s struggle with 
cancer by finding meaning, being grateful, having hope, and relying on faith and spirituality. 
Parents expressed gratitude for how things went for their child, no matter the outcome. The 
sense that “we've been very fortunate” pervaded their experiences as they compared aspects 
of their journey with what they observed other families enduring. Parents’ hope focused on 
slowing or stopping their child’s cancer. At some point though, parents lost hope that their 
child’s cancer could be stopped, regardless of their child’s outcome. They were aware that 
their child’s life was at stake. “We were okay with it [the child’s unexpected death during 
the P1T]. I mean I was not okay with it at the time, but we knew it could happen.” Parents 
found meaning when the time with their child was well spent and had a sense of 
achievement in the cancer journey – on behalf of their child and for themselves as a parent.
Theme Category 3 - Perceptions of child's experiences: “There is something 
about them that is very, very different”—Parents’ widely perceived their child as 
special in two ways. They perceived their child as medically complex, e.g. “he always got 
the 1% side effect.”. And, they described their child in a very positive light (e.g. brave, 
optimistic, resilient), from which parents conveyed deep pride and derived strength. 
Underlying parents’ perceptions was a cherishing of their child and the time they spent 
together on meaningful activities. One parent shared a story of her daughter’s interaction 
with another cancer patient:
“She went over [to a man just diagnosed with cancer] and she said, ‘I just want you 
to know, you got this! You can beat this! … It’s not as bad as what people say it is.’ 
He had said, ‘It’s not?’ She goes, ‘No, you'll have your good days and you'll have 
your bad days, but you'll get through it, I promise.’ …. ‘Another thing, you look 
good bald, so when you're done you might just stay bald.’ He started dying 
laughing and he said, ‘Well, you look good bald too.’ She said, ‘Yeah, it’s just 
taken me awhile to get my baldness.’”
From the parent perspective, children’s understanding of the cancer, its treatments, and 
decision-making was influenced by the child’s age and cognitive ability. The child’s age 
impacted their P1T experience as younger children were “too young to really have any 
conversations about what it [the cancer] meant” and to ask tough questions, and did not 
remember any other way of living. That said, almost all parents reported their children being 
very cooperative with cancer treatments and procedures, e.g. “they didn't really balk at it” 
and “he never complained”. This reflected a maturity beyond their years that the children 
developed through their cancer journey. Regardless of age, parents described how their child 
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“knew how to get what [they] … wanted” and used their cancer diagnosis to achieve their 
goals.
The child’s age and cognitive ability influenced parents’ decisions regarding their child’s 
level of involvement in treatment decision-making. All children ages 10 years and older 
without cognitive challenges were described by parents as making their own treatment 
decisions with parental support. Older children and adolescents had this decision-making 
role despite some parents being less certain of their child’s understanding of their own 
cancer, e.g. “I don’t think he realized the extent of how things had gotten at that point.” The 
lack of parent clarity regarding their child’s understanding of their condition occurred 
despite the child’s presence at and involvement in treatment discussions. “The doctors were 
very good at choosing words that would kind of let us know what was going on, but not so 
much a 12-year-old.” Parents recognized adolescents’ inherent tendency to take risks, and 
still let them make decisions, e.g. “he was a 17-year-old boy, so he was a risk-taker, too. So, 
that [P1T participation] fit right in for him.”
Theme Category 4 - The nature of P1T participation: “The further you get into 
a poor prognosis, the easier a phase I trial becomes”—This theme category 
reflects the elements of parents’ experiences specific to the P1T, and it encompasses a broad 
range of theme clusters, including underlying characteristics of P1Ts, choosing to participate 
in a P1T, ebb and flow of P1Ts, emotional stances towards P1Ts, and the impact of P1T 
participation.
The underlying P1T characteristic impacting parents the most was the uncertainty of P1Ts; 
the sense that “nothing’s ever a given” This uncertainty encompassed having to meet criteria 
to initially start the trial and to continue to the next course of the trial, as well as not 
knowing what the P1T therapy would do to or for their child. One parent stated:
“Nothing's ever a given. Even in medicine that's been proven.…. we knew that… 
everything was a ticking time bomb. … we just knew that certain things would not 
work. … it just seemed like [the P1T] was the one that offered the most hope. And, 
I don't know if that was a tangible hope or not.”
Parents understood there weren’t any guarantees that the P1T would help against their 
child’s cancer. Some clearly expressed that “I knew it wouldn’t help [my child]”, yet were 
still willing to participate given their child’s poor prognosis. The hope that the P1T would 
help slow or stop the child’s cancer was reported by all parents. Parents were realistic in this 
hope, e.g. “with these studies … we aren't even looking for the cancer to shrink; we're just 
looking for it to stay at bay.” Altruism and leaving a legacy were only identified by parents 
of deceased children ages 12 and older as reasons for participation. The appeal of P1Ts was 
a sense of trying something completely novel and of pursuing everything possible to help 
their child, as well as being part of research that potentially could lead to a cure.
There was evidence that P1T participation impacted how a parent managed their child’s 
symptoms. “Him being sick right now … we're trying not to give him any Tylenol or 
anything that could whack his body out.” This resulted from an overriding fear that 
additional medications could exacerbate toxicities (e.g. liver or renal laboratory 
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abnormalities) and cause the child’s premature removal from the P1T. In addition, some 
parents were not educated about palliative care and hospice services until after the P1T 
enrollment, late in the child’s illness. “Nobody ever really counseled us on that. I also had 
this stigma about hospice services because I thought that was giving up, but it turns out 
[hospice services] was a very good decision.”
Overall, parents approached the P1T as “just another medicine” for their child’s cancer. 
Specific advantages parents experienced while participating in a P1T included feeling better 
informed and cared for during the P1T, and having access to more resources and 
opportunities by being at a larger P1T center. Disadvantages included having to wait to start 
P1T therapy, burdens of extra and longer medical appointments as well as additional 
procedures and venipunctures, and a sense of their lives revolving around the P1T. Parents 
strove to minimize the burdens of P1T participation by incorporating enjoyable activities 
around required P1T appointments (i.e. by making visits to the P1T center feel like “a family 
trip… a little get-away”). Despite feeling negative emotions at times, almost without 
exception parents did not regret their child participating in a P1T and recommended P1Ts to 
other parents of children with cancer.
Theme Category 5 - Remembering and forgetting: “Sometimes your brain kind 
of blocks things out”—All parents described a fogginess in their memories of their 
child’s participation in a P1T and cancer treatments in general, e.g. “a lot of it is a blur.” 
This fogginess meant that many specific details were not remembered. One parent shared:
“I'd like to forget it completely... Again, the Ronald McDonald House, … the 
activities we did, the love of the city are all positives. The treatment itself, yeah, I'm 
really not interested in remembering a lot about it.”
Parents whose child was surviving and continuing to pursue P1Ts remembered the specific 
challenges of P1T participation the clearest. Regardless of how much time had lapsed, 
parents remembered seminal events very clearly, including when they received particularly 
devastating news or were deeply offended by clinicians. Parents reported that younger 
children who were long-term survivors did not “remember anything about … cancer 
treatments” in the long run, although they “remember some of the happy things” associated 
with the cancer treatment (i.e. playing with child life specialists). Most parents were not 
concerned with their challenges remembering P1T details, and even took comfort in not 
remembering.
The Essential Structure of Having a Child with Cancer Participate in a P1T
Pervasive throughout parents’ descriptions of their lived experiences during P1T 
participation was a sense of running out of time to find an effective treatment for their child, 
and their need to use well the time they had with their child. Despite unique aspects of P1T 
participation, parents’ experiences were not focused on the P1Ts themselves. Instead, 
parents were focused on their role and responsibilities as a parent, the specialness of their 
child, and their child’s contending with aggressive high-risk cancer to survive. Parents’ 
perceptions of their child’s experiences reflected a sense of pride in their child and how their 
child dealt with the cancer and its treatments. What parents remembered following 
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participation in a P1T reflected what stood out in the experience, and how parents managed 
the P1T experience. Particularly important aspects of the P1T experience included the 
connection with the clinicians who managed the child’s care during the P1T, making the 
choice to continue trying to slow or stop the child’s cancer by participating in a P1T, and 
being burdened by additional requirements when participating in a P1T.
Discussion
The purpose of this study was to address the gap in our understanding of P1T participation 
for children with cancer or their parents, by providing a rich description of parents’ 
experiences during their child’s participation in a P1T. The overarching thread throughout 
parents’ descriptions of their experiences was “we don’t have time to waste”. All 
participants recognized that, due to the advanced nature of their child’s cancer, “the 
commodity is time, and you run out of it, and you don’t get it back.” The meaning of using 
time well differed between families and varied within each families’ cancer journey. In some 
situations, it was a reason for participating in a P1T, in other situations it was a reason to 
stop. Further research is needed to better understand parents’ decision-making related to 
stopping cancer-focused treatment efforts for their child, as well as to understand the role 
children should have in this decision.
Ethicists and clinicians have proposed that the potential benefits of pediatric oncology P1T 
participation may include improved QOL and hope (Barnes, Pressey, Adams, Hensler, & 
Madan-Swain, 2014; Beardsmore & Fitzmaurice, 2002; Carlson, Reilly, & Hitchens, 2005; 
Chang, 2008; Estlin, Cotterill, Pratt, Pearson, & Bernstein, 2000; Gilliam, Madan-Swain, 
Adams, & Pressey, 2013; Oberman & Frader, 2003; Ulrich, Grady, & Wendler, 2004). 
Although this study did not attempt to assess QOL benefits associated with P1T 
participation, study findings confirmed that P1T participation fosters hope to slow or stop 
the child’s cancer. A potential risk of P1T participation posited in the literature was the 
fostering of unrealistic hope (Barnes et al., 2014; Beardsmore & Fitzmaurice, 2002; Chang, 
2008; Gilliam et al., 2013; Oberman & Frader, 2003; Ulrich et al., 2004). Findings did not 
indicate parents had unrealistic hope. Parents were able to be realistic in their expectations 
of direct benefit for their child from the P1T therapy. Parents were fully aware that their 
child’s life was at stake, and that the advanced status of their child’s cancer made it unlikely 
their child would be cured. Parents also seemed to derive benefit from their child’s P1T 
participation through the sense of having tried everything possible, including a novel 
investigational therapy, to help their child. A prospective research study is needed with 
parents to confirm that these benefits, which were reflected on retrospectively by parents, are 
also experienced by parents during P1T participation.
Another risk of P1T participation identified in the literature was the burdening of children 
with additional medical procedures and toxicities (Barnes et al., 2014; Beardsmore & 
Fitzmaurice, 2002; Carlson et al., 2005; Chang, 2008; Estlin et al., 2000; Gilliam et al., 
2013; Oberman & Frader, 2003; Ulrich et al., 2004). This study found the burdens of P1T 
participation for children and parents included additional medical procedures, toxicities, and 
medical appointments, as well as having to wait to start P1T therapy and a sense of their 
lives revolving around meeting the P1T requirements. However, parents took the 
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requirements of the P1T protocol and its requirements seriously and strove to comply, even 
when compliance was burdensome. To make the experience less burdensome, parents 
incorporated enjoyable activities around the P1T requirements (e.g. special activities with 
the child life specialist, or visits to a favorite park). To support the efforts of parents to use 
time with their child well, the medical team can facilitate parents’ efforts to minimize the 
burdens of P1T participation by incorporating enjoyable and meaningful activities around 
required P1T appointments.
A final risk of pediatric oncology P1T participation identified in the literature was 
limitations on opportunities for palliation (Beardsmore & Fitzmaurice, 2002; Oberman & 
Frader, 2003; Ulrich et al., 2004). The study findings provided evidence that P1T 
participation did impact how some parents managed their child’s symptoms. The need to 
ensure the child stayed in the P1T and did not miss doses of the investigational therapy, 
sometimes was prioritized over the child’s symptom management. In addition, some parents 
were not educated about palliative care and / or hospice services until late in the child’s 
illness, after they had enrolled in a P1T. The latter does not seem to reflect the impact of P1T 
participation, but instead appears to reflect the reluctance of clinicians and parents to discuss 
palliative care and / or hospice when there is a focus on continuing cancer treatment. Indeed, 
late palliative care and / or hospice referral has previously been described in the literature as 
a significant problem in general for children with advanced cancer (Levine et al., 2016; 
Moody, Siegel, Scharbach, Cunningham, & Cantor, 2011; Waldman & Wolfe, 2013). These 
study findings highlight the need to simultaneously provide effective palliative care 
throughout the child’s P1T participation (Baker et al., 2008; Meyers et al., 2004). One way 
to achieve this is to ensure palliative care consultations are conducted as part of the P1T 
consenting process, for children that were not already introduced to palliative care services 
(Meyers et al., 2004; Ulrich et al., 2004).
P1T decision-making and consent processes were demonstrated in this study to be impacted 
by the quality of communication between the child, parent, and clinicians. Parents in this 
study specifically highlighted how double-protection (i.e. the phenomenon of both parent 
and child attempting to protect each other) negatively impacted open communication and 
consent processes (Last, 1992). This warrants clinicians and P1T researchers paying 
particular attention during P1T consent conversations to the transparency of communication. 
The best methods for including children in cancer treatment decision-making is now better 
understood through Kelly et al.’s (2016) “Having a Say” construct. This construct 
demonstrates that children trust that their parents and clinicians act in their best interests, 
and depending on the specific circumstances may or may not want to have a say in treatment 
decisions (Kelly et al., 2016). Further research is needed on the role of the “Having a Say” 
construct to facilitate children’s involvement in P1T decision-making. To enhance the 
quality of communication when cancer treatment decisions are made, clinicians should 
consider whether a separate conversation alone with the parent(s) is warranted, in addition to 
a conversation with the parent(s) and child together.
Study findings indicated that parents did not remember many details of their child’s cancer 
treatment experiences in the long term. However, further research is needed to understand 
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whether not remembering is a potentially problematic repression of traumatic memories or a 
less worrisome natural adaptation following a period of significant stress.
Overall, parents did not regret their child participating in a P1T and would recommend P1Ts 
to other parents of children with cancer. There was a notable exception as one parents’ 
experience with the P1T was substantively more negative, despite their child having 
prolonged stable disease with tumor shrinkage from the P1T therapy. This parents’ P1T 
experience was fraught with a sense of disconnectedness from the medical team, with the 
child fighting taking the oral investigational medication, as well as with doubts as to whether 
they were doing the right thing for their child. The reasons behind this were difficult to fully 
appreciate without having captured the medical team’s perspective. However, this parent was 
also the only one who really struggled with the initial decision to participate in the P1T. It is 
important to not dismiss this one parent’s experience as an outlier, as it may reflect other 
unreported problematic P1T experiences. The authors recommend that in future research, an 
in-depth multiple case study be conducted when profoundly negative participant experiences 
are identified, in order to capture the perspectives of the parent, medical team, and child and 
to elucidate the causes of negative P1T experiences. In addition, P1T researchers and 
clinicians should explore with parents the reasons behind hesitancies to participate or 
continue in a P1T. It is particularly important that P1T researchers and clinicians are aware 
of the significance of an offer of a P1T for parents of children with high-risk cancer, and the 
impact that a pre-existing parent / clinician relationship has on parents’ ability to decline a 
P1T offer or to share concerns with clinicians during a P1T.
Limitations
The primary limitations of this study were the lack of racial, ethnic, social, and gender 
diversity in the accrued sample, and the lower-than-anticipated response rates from medical 
centers creating concerns for self-selection bias by those who chose to participate. In 
addition, a fuller description of pediatric oncology P1T experiences would include the 
child’s perspective. Due to the shortened life expectancy of children enrolled in P1Ts, and 
the relatively small number of children enrolled per trial, obtaining the child’s perspective 
was not feasible outside of a prospective, multi-center study. Lastly, this study captured 
parents’ experiences retrospectively and parents’ perceptions of their experiences may have 
altered with the passing of time.
Conclusions
Study findings are generally reassuring to P1T researchers and pediatric oncologists who 
consider recommending P1Ts for children with cancer. For parents of a child with high-risk 
cancer, a P1T represents a novel treatment option with potentially more acceptable 
toxicities. Although some concerns were raised by study findings regarding the experiences 
of parents and children in P1Ts, these reflect opportunities for improving the support 
provided to P1T participants. Parents who describe burdens in P1Ts would not dissuade 
other parents of children with high-risk cancer from participating, and indeed would 
continue to pursue other P1Ts for their own child with cancer.
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Table 1
Examples of Significant Statements, Restatements, and Formulated Meanings Developed During Data 
Analysis
Significant Statements (From Original 
Interview Transcript)
Restatements (Developed by the 
Authors)
Formulated Meanings (Developed by the 
Authors)
We just kept telling ourselves that even if 
we have these hesitancies and we think 
that may be... pushing big pharma or 
whatever, maybe it's also because they 
want the best for [child’s name].
Family kept telling themselves that even 
if they have these hesitancies and family 
thinks that the doctors may be pushing 
big pharmaceutical companies or 
whatever, maybe it’s also because the 
doctors want the best for their child.
Aware of competing interests. Wary of clinical 
trials and interests of big pharmaceutical 
companies. Hoping the doctors were involved in 
clinical trials because it was best for children 
with cancer, and for their child; for altruistic and 
not ambitious reasons.
He was all excited about doing that as 
well, sending samples out to wherever it 
needed to go. Knowing that it wouldn't 
help him, but it would hopefully help other 
people in the future.
Adolescent was excited about sending 
blood for research. Adolescent knew that 
sending the blood would not help him. 
Adolescent wanted to help others in the 
future.
It was important to the adolescent to contribute to 
future scientific advances. Adolescent understood 
that the research samples would not provide 
direct benefit to himself. Proud of adolescent’s 
selflessness and for who adolescent was – 
someone for whom altruism was an important 
part of the reason for being involved with 
research.
I think she would have rather - and I don't 
really blame her since she had a port, or 
whatever - she would rather go have 
medicine put in her than have to take a 
pill.
Parent thinks child would have rather go 
have medicine put in [port] than have to 
take a pill.
Would have been easier to do IV medications 
than to have to take medications at home.
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Table 2
Characteristics of the Sample and their P1T Experiences *
Item n (%)
Parent’s Annual Income (N=11 parents)
 <$40,000 0 (0)
 $40–$59,999 3 (27.3)
 $60–99,999 2 (18.2)
 >$100,000 4 (36.4)
 Don’t Know 2 (18.2)
Parent’s Education (N=11 parents)
 Less Than 12th Grade 0 (0)
 High School Graduate 2 (18.2)
 Some College or Professional Training 2 (18.2)
 College Graduate 2 (18.2)
 Graduate or Professional Degree 5 (45.4)
Distance from P1T Center (reported for N=10 children)
 Less Than 10 Miles 0 (0)
 10 to 29 Miles 3 (30)
 30 to 89 Miles 2 (20)
 90 to 239 Miles 3 (30)
 More Than 240 Miles 2 (20)
Child’s Diagnosis (N=10 children)
 Sarcoma 6 (60)
 Brain Stem Glioma 1 (10)
 Other Brain Tumor 2 (20)
 Neuroblastoma 1 (10)
 Leukemia 1 (10)
Timing of Removal from P1Ts (N=15 trials)
 Middle of Course 13 (20)
 End of Course 1 3 (20)
 During Course 2 2 (13.3)
 End of Course 3 1 (6.7)
 After Course 3 5 (33.3)
 Completed Trial 1 (6.7)
Reasons Removed from P1Ts (N=15 trials)
 Adverse Events / Toxicities 5 (33.3)
 Disease Progression 8 (53.3)
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Item n (%)
 Death 1 (6.7)
 Completed Trial 1 (6.7)
Best Overall Response to P1Ts (N=15 trials)
 Progressive Disease 5 (33.3)
 Stable Disease 5 (33.3)
 Partial Response 2 (13.3)
 Complete Response 1 (6.7)
 Inevaluable / Unknown Response 2 (13.3)
*N=11 parents of N=10 children, enrolled in a total of N=15 phase I clinical trials.
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Table 3
Theme Clusters and Themes Associated with the Theme Category ‘Being the Parent of a Child with High-
Risk Cancer’
Theme Clusters Themes
Being fully responsible for child's well-being: “It's all on our shoulders”
• Child fully relying on parent
• Advocating for child when needed: “If you don't, then your child's going to get pushed around”
• Protecting child
• Being vigilant
• Prioritizing child’s needs and desires over everything else
• Encouraging child to keep trying: “He wasn't going to be at home ... in bed giving up”
• Needing to find a way to help child get better
• Needing to be an expert
• Not having anyone to blame if treatments don't work
• Knowing child and child's medical condition better than anyone: “They thought they knew better than I did”
• Doing everything possibly can for child
Aligning with child: “We would quit whenever she wanted to”
• Looking to child for direction: “If that's what she wants to do ... she knows how she feels”
• Striving for open communication with child: “We don’t surprise her with anything. We talk about things.”
• Needing child to agree with plan: “I was just very hopeful that she would say, yeah mom, let's do this”
• Being on the same page: “She was willing to do it and we were willing to do it, so we tried whatever”
• Becoming misaligned: “When she started resisting it was very weird for us because she's always been so 
accepting”
Parental suffering
• Indescribable angst
• Watching child suffer
• Fearful of harming child
• Losing oneself in child's journey
• Feeling isolated and alone
• Doubting OR questioning own abilities
• Living with regrets: “I just wish I'd had a little bit more power, a little bit more strength, a little bit more 
knowledge”
• Feeling overwhelmed with what have to handle: Trying to keep up with moving treadmill as speed is being 
increased
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